Read by QxMD icon Read

Cancer methylphenidate

Zhenyang Jiang, Harriet Butler-Bowen, Teresa Rodriguez, Marie C Garcon, Melissa Hennessey Smith, Valerie Relias, Muhammad Wasif Saif
BACKGROUND: Fatigue is a common but devastating symptom for advanced pancreatic cancer (APC) patients. To date, no proven treatment exists. Methylphenidate (MPH) showed inconsistent results in treating other cancer related fatigue. We performed a retrospective study to assess MPH in ameliorating fatigue in APC patients. METHODS: We retrospectively reviewed our clinic APC patients' records who visited from 06/2011 - 11/2014. Fatigue was assessed by Visual Analog Fatigue Scale (VAFS) and classified as grade 1 (VAFS 1-3), grade 2 (VAFS 4-6) and grade 3 (VAFS 7-10) to correspond with CTCAE V4...
October 2016: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
Donald R Sullivan, Solange Mongoue-Tchokote, Motomi Mori, Elizabeth Goy, Linda Ganzini
OBJECTIVE: To determine the effectiveness of methylphenidate for depression treatment in advanced cancer patients. METHODS: An 18-day randomized, double-blind, placebo-controlled clinical trial of methylphenidate for treatment of depression in selective serotonin reuptake inhibitor (SSRI)-treated patients with advanced cancer in hospice or receiving palliative care. The primary outcome was depression remission, defined as a ≥50% reduction in score on the Montgomery-Asberg Depression Rating Scale...
July 18, 2016: Psycho-oncology
Martin Mücke, Mochamat, Henning Cuhls, Vera Peuckmann-Post, Ollie Minton, Patrick Stone, Lukas Radbruch
BACKGROUND: In palliative care patients, fatigue can be severely debilitating and is often not counteracted with rest, thereby impacting daily activity and quality of life. Further complicating issues are the multidimensionality, subjective nature and lack of a consensus definition of fatigue. The review aimed to evaluate the efficacy of pharmacological treatments for fatigue in palliative care, with a focus on patients at an advanced stage of disease, including patients with cancer and other chronic diseases...
March 2016: Journal of Cachexia, Sarcopenia and Muscle
David E Vance, Jennifer Sandson Frank, Jennifer Bail, Kristen L Triebel, Lindsay M Niccolai, Adam Gerstenecker, Karen Meneses
BACKGROUND: Cognitive deficits are distressing adverse effects of chemotherapy that have a negative effect on quality of life in breast cancer survivors (BCSs). Cognitive deficits in cancer survivors are a top research and clinical practice priority. OBJECTIVE: The aims of this study were to describe cognitive deficits that occur after chemotherapy, describe deficits in BCSs treated with chemotherapy within a framework of cognitive reserve and neuroplasticity, and discuss cognitive interventions (ie, cognitive training interventions, compensatory strategies with cognitive training interventions, pharmacological interventions, and complementary and integrative medicine interventions)...
February 25, 2016: Cancer Nursing
D Qu, Z Zhang, X Yu, J Zhao, F Qiu, J Huang
Cancer-related fatigue (CRF) is a common symptom affecting 60-90% of cancer survivors, and effective management for CRF is not yet available. Recently, an increasing number of trials examining the use of psychotropic drugs for the treatment of CRF have been performed, but these trials have yielded inconsistent results. Therefore, we conducted a meta-analysis aimed at assessing the effect and safety of psychotropic drugs for the management of CRF. Ten eligible trials of the psychotropic drugs methylphenidate and modafinil in a total of 1582 participants treated for CRF were subjected to statistical analyses...
October 21, 2015: European Journal of Cancer Care
David R Bonsall, Hyunji Kim, Catherine Tocci, Awa Ndiaye, Abbey Petronzio, Grace McKay-Corkum, Penny C Molyneux, Thomas E Scammell, Mary E Harrington
Fatigue is a disabling symptom in patients with multiple sclerosis and Parkinson's Disease, and is also common in patients with traumatic brain injury, cancer, and inflammatory disorders. Little is known about the neurobiology of fatigue, in part due to the lack of an approach to induce fatigue in laboratory animals. Fatigue is a common response to systemic challenge by pathogens, a response in part mediated through action of the pro-inflammatory cytokine interleukin-1 beta (IL-1β). We investigated the behavioral responses of mice to IL-1β...
2015: PloS One
Eduardo Bruera
No abstract text is available yet for this article.
September 2015: Journal of Pain and Symptom Management
Martin Mücke, Henning Cuhls, Vera Peuckmann-Post, Ollie Minton, Patrick Stone, Lukas Radbruch
BACKGROUND: This review updates the original review, 'Pharmacological treatments for fatigue associated with palliative care' and also incorporates the review 'Drug therapy for the management of cancer-related fatigue'.In healthy individuals, fatigue is a protective response to physical or mental stress, often relieved by rest. By contrast, in palliative care patients' fatigue can be severely debilitating and is often not counteracted with rest, thereby impacting daily activity and quality of life...
2015: Cochrane Database of Systematic Reviews
Geoffrey K Mitchell, Janet R Hardy, Catherine J Nikles, Sue-Ann S Carmont, Hugh E Senior, Philip J Schluter, Phillip Good, David C Currow
CONTEXT: Fatigue is common in life-limiting cancer. Methylphenidate (MPH), a psychostimulant, may be a useful therapy. Gathering evidence in patients with advanced cancer can be challenging. OBJECTIVES: To determine if MPH improves cancer-related fatigue in people with advanced cancer. METHODS: N-of-1 trials are multicycle, double-blind, randomized, controlled crossover trials using standardized measures of effect in individuals. They are normally used to assess treatment effects in individuals...
September 2015: Journal of Pain and Symptom Management
Sriram Yennurajalingam, Eduardo Bruera
Cancer-related fatigue (CRF) is the most common and debilitating symptom in patients with cancer. Currently, there are very limited pharmacological interventions to effectively treat CRF. In this article, the authors review various pharmacological interventions for CRF and propose future direction for further research. Methylphenidate is the most studied pharmacological agent for the treatment of CRF. Various pharmacological studies have suggested benefit of corticosteroids, especially in terminally ill patients for a short period...
September 2014: Cancer Journal
Sharon M Castellino, Nicole J Ullrich, Megan J Whelen, Beverly J Lange
Survivors of childhood cancer frequently experience cancer-related cognitive dysfunction, commonly months to years after treatment for pediatric brain tumors, acute lymphoblastic leukemia (ALL), or tumors involving the head and neck. Risk factors for cancer-related cognitive dysfunction include young age at diagnosis, treatment with cranial irradiation, use of parenteral or intrathecal methotrexate, female sex, and pre-existing comorbidities. Limiting use and reducing doses and volume of cranial irradiation while intensifying chemotherapy have improved survival and reduced the severity of cognitive dysfunction, especially in leukemia...
August 2014: Journal of the National Cancer Institute
Crystal S Denlinger, Jennifer A Ligibel, Madhuri Are, K Scott Baker, Wendy Demark-Wahnefried, Debra L Friedman, Mindy Goldman, Lee Jones, Allison King, Grace H Ku, Elizabeth Kvale, Terry S Langbaum, Kristin Leonardi-Warren, Mary S McCabe, Michelle Melisko, Jose G Montoya, Kathi Mooney, Mary Ann Morgan, Javid J Moslehi, Tracey O'Connor, Linda Overholser, Electra D Paskett, Muhammad Raza, Karen L Syrjala, Susan G Urba, Mark T Wakabayashi, Phyllis Zee, Nicole R McMillian, Deborah A Freedman-Cass
Cognitive impairment is a common complaint among cancer survivors and may be a consequence of the tumors themselves or direct effects of cancer-related treatment (eg, chemotherapy, endocrine therapy, radiation). For some survivors, symptoms persist over the long term and, when more severe, can impact quality of life and function. This section of the NCCN Guidelines for Survivorship provides assessment, evaluation, and management recommendations for cognitive dysfunction in survivors. Nonpharmacologic interventions (eg, instruction in coping strategies; management of distress, pain, sleep disturbances, and fatigue; occupational therapy) are recommended, with pharmacologic interventions as a last line of therapy in survivors for whom other interventions have been insufficient...
July 2014: Journal of the National Comprehensive Cancer Network: JNCCN
Eugenia Sinita, David Coghill
Psychostimulants play a central role in the management of ADHD. Here we review the evidence pertaining to the use of methylphenidate, dexamphetamine and related amphetamine salts, the prodrug lisdexamfetamine and modafinil for the management of comorbid ADHD and non-ADHD indications. There is a growing consensus that stimulant medications are helpful at improving the emotional dysregulation and lability, and oppositional and conduct symptoms that are often associated with ADHD. There is some evidence that psychostimulants may improve outcomes in those with treatment resistant depression, reduce negative symptoms and improve cognitive performance in schizophrenia, and that methylphenidate may reduce binge eating in those with bulimia nervosa...
December 2014: Neuropharmacology
Kathryn J Ruddy, Debra Barton, Charles L Loprinzi
No abstract text is available yet for this article.
June 20, 2014: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Anna Spathis, Kate Fife, Fiona Blackhall, Susan Dutton, Ronja Bahadori, Rose Wharton, Mary O'Brien, Patrick Stone, Tim Benepal, Nick Bates, Bee Wee
PURPOSE: Fatigue is a distressing symptom occurring in more than 60% of patients with cancer. The CNS stimulants modafinil and methylphenidate are recommended for the treatment of cancer-related fatigue, despite a limited evidence base. We aimed to evaluate the efficacy and tolerability of modafinil in the management of fatigue in patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Adults with advanced NSCLC and performance status of 0 to 2, who were not treated with chemotherapy or radiotherapy within the last 4 weeks, were randomly assigned to daily modafinil (100 mg on days 1 to 14; 200 mg on days 15 to 28) or matched placebo...
June 20, 2014: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Hyoyoung Kim, Won Gi Yoo, Junhyung Park, Heebal Kim, Byeong-Chul Kang
Single-nucleotide polymorphisms (SNPs) have been emerging out of the efforts to research human diseases and ethnic disparities. A semantic network is needed for in-depth understanding of the impacts of SNPs, because phenotypes are modulated by complex networks, including biochemical and physiological pathways. We identified ethnicity-specific SNPs by eliminating overlapped SNPs from HapMap samples, and the ethnicity-specific SNPs were mapped to the UCSC RefGene lists. Ethnicity-specific genes were identified as follows: 22 genes in the USA (CEU) individuals, 25 genes in the Japanese (JPT) individuals, and 332 genes in the African (YRI) individuals...
March 2014: Genomics & Informatics
Patrick O Richard, Neil E Fleshner, Jaimin R Bhatt, Karen M Hersey, Rehab Chahin, Shabbir M H Alibhai
OBJECTIVES: To investigate whether methylphenidate can alleviate fatigue, as measured by the Functional Assessment of Cancer Therapy: Fatigue subscale, in men with prostate cancer (PCa) treated with a luteinizing hormone-releasing hormone (LHRH) for a minimum of 6 months, and to assess changes in global fatigue and quality of life (QoL) as measured by the Bruera Global Fatigue Severity Scale (BFS) and the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36), respectively. PARTICIPANTS AND METHODS: We performed a single-centre, randomised, double-blind, placebo-controlled trial with the aim of recruiting 128 participants...
November 2015: BJU International
Carlos Centeno, Alvaro Sanz, Miguel Angel Cuervo, Daniel Ramos, Silvia Hernansanz, Jesús Gonzalez, Maria Jose Almaraz, Marcos Lama, Francisco Vara, María Nabal, Antonio Pascual
INTRODUCTION: Methylphenidate is a psychostimulant that has been used to relieve depressive symptoms in advanced cancer patients. No studies compare its efficacy against placebo in this group of patients. OBJECTIVE: To explore the efficacy of methylphenidate compared with placebo in the relief of depressive symptoms in advanced cancer patients. MATERIAL AND METHODS: A multicentre, double-blind, randomised placebo-controlled clinical trial was undertaken comparing the efficacy of methylphenidate and placebo in depressive symptoms...
December 2012: BMJ Supportive & Palliative Care
Lauren Rayner, Matthew Hotopf
No abstract text is available yet for this article.
December 2012: BMJ Supportive & Palliative Care
Chong Guan Ng, Marco P M Boks, Kit C B Roes, Nor Zuraida Zainal, Ahmad Hatim Sulaiman, Seng Beng Tan, Niek J de Wit
This is a 4 week, randomized, double-blind, placebo-controlled study to examine the effects of methylphenidate as add-on therapy to mirtazapine compared to placebo for treatment of depression in terminally ill cancer patients. It involved 88 terminally ill cancer patients from University of Malaya Medical Centre, Kuala Lumpur, Malaysia. They were randomized and treated with either methylphenidate or placebo as add on to mirtazapine. The change in Montgomery-Åsberg Depression Rating Scale (MADRS) score from baseline to day 3 was analyzed by linear regression...
April 2014: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"